NUTM1 and nut midline carcinoma: When further segregated based on NMC gene-fusion subtype (Figure 2B), iBET treatment was significantly more effective in NMC cell lines expressing the BRD4-NUTM1 ex11:ex2 variant compared to those with a BRD4-NUTM1 ex15:ex2 fusion (p < 0.01) or non-NMC carcinomas (p < 0.0001).